Hypophosphatemia in Patients With Multiple Myeloma

Hypophosphatemia is among the most common electrolyte abnormalities, especially among patients with underlying malignancies, and is frequently associated with adverse prognoses. Phosphorus levels are regulated through a number of mechanisms, including parathyroid hormone (PTH), fibroblast growth fac...

Full description

Saved in:
Bibliographic Details
Published inCurēus (Palo Alto, CA) Vol. 15; no. 6; p. e40487
Main Authors Cancarevic, Ivan, Ilyas, Usman, Nassar, Mahmoud
Format Journal Article
LanguageEnglish
Published United States Springer Nature B.V 15.06.2023
Cureus
Subjects
Bisphosphonates
Cancer
Diabetes
Disease
Endocrine system
Fibroblasts
Growth factors
Hypercalcemia
Internal Medicine
Kidneys
Metabolism
Multiple myeloma
Nephrology
Oncology
Phosphates
Phosphorus
Regulation
Squamous cell carcinoma
Tomography
Tumors
electrolyte disturbances
multiple myeloma
hypophosphatemia
electrolyte
phosphorus
Online AccessGet full text

Cover

Abstract Hypophosphatemia is among the most common electrolyte abnormalities, especially among patients with underlying malignancies, and is frequently associated with adverse prognoses. Phosphorus levels are regulated through a number of mechanisms, including parathyroid hormone (PTH), fibroblast growth factor-23 (FGF-23), vitamin D, and other electrolyte levels themselves. Clinically, the findings are nonspecific, and the diagnosis is frequently delayed. This article is a narrative literature review. The PubMed database was searched for relevant articles pertaining to hypophosphatemia causes and consequences in patients suffering from multiple myeloma. We found a variety of causes of hypophosphatemia in patients with multiple myeloma. Tumor-induced osteopenia, although more common among patients with small squamous cell carcinomas, can occur with multiple myeloma as well. Additionally, both light chains themselves and medications can trigger Fanconi syndrome, which leads to phosphorus wasting by the kidney. Bisphosphonates, in addition to being a possible cause of Fanconi syndrome, lead to a decrease in calcium levels, which then stimulates parathyroid hormone (PTH) release, predisposing the patient to significant hypophosphatemia. Additionally, many of the more modern medications used to manage multiple myeloma have been associated with hypophosphatemia. A better understanding of those mechanisms may give clinicians a clearer idea of which patients may need more frequent screening as well as what the potential triggers in the individual patient may be.
AbstractList Hypophosphatemia is among the most common electrolyte abnormalities, especially among patients with underlying malignancies, and is frequently associated with adverse prognoses. Phosphorus levels are regulated through a number of mechanisms, including parathyroid hormone (PTH), fibroblast growth factor-23 (FGF-23), vitamin D, and other electrolyte levels themselves. Clinically, the findings are nonspecific, and the diagnosis is frequently delayed. This article is a narrative literature review. The PubMed database was searched for relevant articles pertaining to hypophosphatemia causes and consequences in patients suffering from multiple myeloma. We found a variety of causes of hypophosphatemia in patients with multiple myeloma. Tumor-induced osteopenia, although more common among patients with small squamous cell carcinomas, can occur with multiple myeloma as well. Additionally, both light chains themselves and medications can trigger Fanconi syndrome, which leads to phosphorus wasting by the kidney. Bisphosphonates, in addition to being a possible cause of Fanconi syndrome, lead to a decrease in calcium levels, which then stimulates parathyroid hormone (PTH) release, predisposing the patient to significant hypophosphatemia. Additionally, many of the more modern medications used to manage multiple myeloma have been associated with hypophosphatemia. A better understanding of those mechanisms may give clinicians a clearer idea of which patients may need more frequent screening as well as what the potential triggers in the individual patient may be.
Hypophosphatemia is among the most common electrolyte abnormalities, especially among patients with underlying malignancies, and is frequently associated with adverse prognoses. Phosphorus levels are regulated through a number of mechanisms, including parathyroid hormone (PTH), fibroblast growth factor-23 (FGF-23), vitamin D, and other electrolyte levels themselves. Clinically, the findings are nonspecific, and the diagnosis is frequently delayed. This article is a narrative literature review. The PubMed database was searched for relevant articles pertaining to hypophosphatemia causes and consequences in patients suffering from multiple myeloma. We found a variety of causes of hypophosphatemia in patients with multiple myeloma. Tumor-induced osteopenia, although more common among patients with small squamous cell carcinomas, can occur with multiple myeloma as well. Additionally, both light chains themselves and medications can trigger Fanconi syndrome, which leads to phosphorus wasting by the kidney. Bisphosphonates, in addition to being a possible cause of Fanconi syndrome, lead to a decrease in calcium levels, which then stimulates parathyroid hormone (PTH) release, predisposing the patient to significant hypophosphatemia. Additionally, many of the more modern medications used to manage multiple myeloma have been associated with hypophosphatemia. A better understanding of those mechanisms may give clinicians a clearer idea of which patients may need more frequent screening as well as what the potential triggers in the individual patient may be.
Hypophosphatemia is among the most common electrolyte abnormalities, especially among patients with underlying malignancies, and is frequently associated with adverse prognoses. Phosphorus levels are regulated through a number of mechanisms, including parathyroid hormone (PTH), fibroblast growth factor-23 (FGF-23), vitamin D, and other electrolyte levels themselves. Clinically, the findings are nonspecific, and the diagnosis is frequently delayed. This article is a narrative literature review. The PubMed database was searched for relevant articles pertaining to hypophosphatemia causes and consequences in patients suffering from multiple myeloma. We found a variety of causes of hypophosphatemia in patients with multiple myeloma. Tumor-induced osteopenia, although more common among patients with small squamous cell carcinomas, can occur with multiple myeloma as well. Additionally, both light chains themselves and medications can trigger Fanconi syndrome, which leads to phosphorus wasting by the kidney. Bisphosphonates, in addition to being a possible cause of Fanconi syndrome, lead to a decrease in calcium levels, which then stimulates parathyroid hormone (PTH) release, predisposing the patient to significant hypophosphatemia. Additionally, many of the more modern medications used to manage multiple myeloma have been associated with hypophosphatemia. A better understanding of those mechanisms may give clinicians a clearer idea of which patients may need more frequent screening as well as what the potential triggers in the individual patient may be.Hypophosphatemia is among the most common electrolyte abnormalities, especially among patients with underlying malignancies, and is frequently associated with adverse prognoses. Phosphorus levels are regulated through a number of mechanisms, including parathyroid hormone (PTH), fibroblast growth factor-23 (FGF-23), vitamin D, and other electrolyte levels themselves. Clinically, the findings are nonspecific, and the diagnosis is frequently delayed. This article is a narrative literature review. The PubMed database was searched for relevant articles pertaining to hypophosphatemia causes and consequences in patients suffering from multiple myeloma. We found a variety of causes of hypophosphatemia in patients with multiple myeloma. Tumor-induced osteopenia, although more common among patients with small squamous cell carcinomas, can occur with multiple myeloma as well. Additionally, both light chains themselves and medications can trigger Fanconi syndrome, which leads to phosphorus wasting by the kidney. Bisphosphonates, in addition to being a possible cause of Fanconi syndrome, lead to a decrease in calcium levels, which then stimulates parathyroid hormone (PTH) release, predisposing the patient to significant hypophosphatemia. Additionally, many of the more modern medications used to manage multiple myeloma have been associated with hypophosphatemia. A better understanding of those mechanisms may give clinicians a clearer idea of which patients may need more frequent screening as well as what the potential triggers in the individual patient may be.
Author Ilyas, Usman
Nassar, Mahmoud
Cancarevic, Ivan
AuthorAffiliation 2 Internal Medicine, Icahn School of Medicine at Mount Sinai, NYC Health + Hospitals/Queens, New York, USA
1 Internal Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, New York, USA
AuthorAffiliation_xml – name: 1 Internal Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, New York, USA
– name: 2 Internal Medicine, Icahn School of Medicine at Mount Sinai, NYC Health + Hospitals/Queens, New York, USA
Author_xml – sequence: 1
  givenname: Ivan
  surname: Cancarevic
  fullname: Cancarevic, Ivan
– sequence: 2
  givenname: Usman
  surname: Ilyas
  fullname: Ilyas, Usman
– sequence: 3
  givenname: Mahmoud
  surname: Nassar
  fullname: Nassar, Mahmoud
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37342302$$D View this record in MEDLINE/PubMed
BookMark eNpdkc9LwzAYhoNM3Jy7eZaCFw92fvnVpCeRoU7Y0IPiMWRp5jLapjatsP_e6uZQT_kgDy_P973HqFf60iJ0imEsBE-vTFvbNowZMCkO0IDgRMYSS9b7NffRKIQ1AGAQBAQcoT4VlBEKZIDIdFP5auVDtdKNLZyOXBk96cbZsgnRq2tW0bzNG1flNppvbO4LfYIOlzoPdrR7h-jl7vZ5Mo1nj_cPk5tZbChAE5NsYbCwGSMJyDSTRnOQNMloRrQhgiSaEgNWgpZskUhJEg6GJ5xiSzPGOR2i621u1S4Km5nOqNa5qmpX6HqjvHbq70_pVurNfygMRKQM0i7hYpdQ-_fWhkYVLhib57q0vg2KSNIZYYJZh57_Q9e-rctuv46iWOAUeNJRZ7-V9i4_9-yAyy1gah9CbZd7BIP6akxtG1PfjdFPvvuH_w
Cites_doi 10.1016/j.ecl.2016.09.013
10.1159/000516390
10.7326/0003-4819-131-4-199908170-00026
10.1038/s41375-019-0384-1
10.1038/s41598-018-32432-z
10.1016/j.afos.2018.12.001
10.1007/s40264-019-00888-1
10.1002/(SICI)1097-0142(19961001)78:7<1384::AID-CNCR3>3.0.CO;2-L
10.1371/journal.pone.0122885
10.1007/s11892-020-01335-7
10.1067/j.cpradiol.2018.06.005
10.1097/MJT.0000000000000095
10.1681/ASN.2012040388
10.1038/s41581-018-0087-2
10.4158/ACCR-2020-0389
10.1002/(sici)1097-4598(199805)21:5<650::aid-mus14>3.0.co;2-z
10.1016/j.clinimag.2019.04.007
10.1016/j.jamcollsurg.2017.06.012
10.1016/j.eucr.2016.11.019
10.3389/fendo.2021.733793
10.1007/s00277-018-3572-6
10.1177/0897190015624050
10.1093/qjmed/hcr104
10.1093/ckj/sfw086
10.1177/0004563213510708
10.1359/jbmr.1997.12.9.1502
10.1200/JCO.1991.9.8.1495
10.1016/s0272-6386(97)90319-x
10.1111/vox.13064
10.2174/1574886311666160426141647
10.1111/j.1365-2265.1995.tb02621.x
10.1097/01.rlu.0000170012.06271.76
10.1080/0886022X.2020.1735417
10.3390/ijms22126208
10.1182/blood-2019-123506
10.1038/nrc2189
10.1016/j.bone.2008.01.027
10.1177/0003134820949517
10.1002/14651858.CD003188.pub4
10.18632/oncotarget.3794
10.1093/qjmed/hct258
10.1007/s12288-021-01470-5
10.1007/s10147-016-1063-0
10.36290/vnl.2021.130
10.1136/bcr.10.2011.4950
10.1053/j.ajkd.2012.03.024
10.1016/j.ecl.2021.08.002
10.1038/ki.2008.356
10.1186/1471-2369-14-13
10.1007/s00277-020-04351-5
10.1182/blood-2012-04-422683
10.18926/AMO/30707
10.1681/ASN.2015050581
10.2147/OTT.S81022
10.1182/blood-2019-128519
10.1016/s0272-6386(12)80820-1
10.1093/ckj/sfab078
10.1056/NEJMoa0806285
10.1016/j.jbspin.2004.10.012
10.1016/j.pcl.2018.09.002
10.1530/EDM-22-0300
10.1016/s0889-8529(02)00079-8
10.1056/NEJMct1004903
10.1177/0885066620940274
10.1093/qjmed/hcq039
10.1016/S2213-8587(19)30426-7
10.1183/13993003.02187-2017
10.1177/0004563214521399
10.1161/CIRCHEARTFAILURE.121.008385
10.1016/S0020-1383(16)30015-8
10.1097/00000441-200302000-00007
10.1097/MPA.0000000000001952
10.1042/CS20201290
10.1016/j.amjms.2016.04.013
10.1186/bcr1384
10.1007/s00223-020-00691-6
10.1016/j.bone.2021.116077
10.7759/cureus.3947
10.1053/j.ajkd.2021.12.015
10.1016/j.clnu.2020.09.045
10.1016/j.bone.2006.01.163
10.1007/s00223-021-00843-2
10.1159/000509768
10.7861/clinmedicine.17-3-270
10.1146/annurev.med.051308.111339
10.1007/s11914-017-0397-5
10.1016/j.bone.2011.02.003
10.1002/cncr.29533
10.1530/ERC-11-0006
10.1080/10428194.2021.2005044
10.2147/IJGM.S319717
10.1097/MNH.0000000000000715
10.1182/blood.V106.11.2556.2556
ContentType Journal Article
Copyright Copyright © 2023, Cancarevic et al.
Copyright © 2023, Cancarevic et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright © 2023, Cancarevic et al. 2023 Cancarevic et al.
Copyright_xml – notice: Copyright © 2023, Cancarevic et al.
– notice: Copyright © 2023, Cancarevic et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Copyright © 2023, Cancarevic et al. 2023 Cancarevic et al.
DBID AAYXX
CITATION
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
COVID
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.7759/cureus.40487
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
Coronavirus Research Database
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed
Publicly Available Content Database

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2168-8184
ExternalDocumentID PMC10279409
37342302
10_7759_cureus_40487
Genre Journal Article
Review
GroupedDBID 53G
5VS
7X7
8FI
8FJ
AAYXX
ABUWG
ADBBV
AFKRA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BCNDV
BENPR
BPHCQ
BVXVI
CCPQU
CITATION
FYUFA
HMCUK
HYE
KQ8
M48
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RPM
UKHRP
3V.
ADRAZ
GROUPED_DOAJ
NPM
OK1
7XB
8FK
AZQEC
COVID
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c300t-2dbc17ed426089d8ca50836d3d2ac2726a32c0e80a84b6882650c56531e3d4553
IEDL.DBID M48
ISSN 2168-8184
IngestDate Thu Aug 21 18:36:59 EDT 2025
Fri Jul 11 11:55:02 EDT 2025
Mon Jun 30 07:28:11 EDT 2025
Thu Jan 02 22:31:42 EST 2025
Tue Jul 01 01:17:58 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords electrolyte disturbances
multiple myeloma
hypophosphatemia
electrolyte
phosphorus
Language English
License Copyright © 2023, Cancarevic et al.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c300t-2dbc17ed426089d8ca50836d3d2ac2726a32c0e80a84b6882650c56531e3d4553
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.7759/cureus.40487
PMID 37342302
PQID 2831719056
PQPubID 2045583
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10279409
proquest_miscellaneous_2828361214
proquest_journals_2831719056
pubmed_primary_37342302
crossref_primary_10_7759_cureus_40487
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-06-15
PublicationDateYYYYMMDD 2023-06-15
PublicationDate_xml – month: 06
  year: 2023
  text: 2023-06-15
  day: 15
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Palo Alto
– name: Palo Alto (CA)
PublicationTitle Curēus (Palo Alto, CA)
PublicationTitleAlternate Cureus
PublicationYear 2023
Publisher Springer Nature B.V
Cureus
Publisher_xml – name: Springer Nature B.V
– name: Cureus
References Hideshima T (ref11) 2007; 7
Bosman A (ref90) 2021; 12
Smith ER (ref29) 2014; 51
Sin JC (ref8) 2021; 36
Wagner J (ref9) 2021; 50
Favus MJ (ref69) 2010; 363
Bonjour JP (ref25) 1990; 332
Powles T (ref72) 2006; 8
Shane E (ref43) 1997; 12
Liamis G (ref89) 2010; 103
Bergwitz C (ref3) 2010; 61
Mukkamalla SK (ref13) 2021; 22
Gonciulea AR (ref28) 2017; 46
Yoshida T (ref20) 2017; 22
Clark SL (ref80) 2016; 29
Tiberi S (ref64) 2018; 51
Zheng J (ref23) 2017; 225
Ivey-Miranda JB (ref30) 2021; 14
Wong P (ref22) 2021; 87
Florenzano P (ref1) 2020; 8
Siddiqui MF (ref5) 1998; 21
Luciani A (ref54) 2016; 27
Reece DE (ref88) 2005; 106
Stone MJ (ref18) 1982; 12
Melnick JZ (ref63) 1994; 23
Hall AM (ref61) 2014; 107
Yui JC (ref66) 2021; 116
Weisbord SD (ref94) 2003; 325
Ariyoshi N (ref6) 2016; 352
Rayamajhi SJ (ref40) 2019; 56
Yashar D (ref82) 2022; 63
Edwards CM (ref12) 2008; 42
Vervloet M (ref26) 2019; 15
Clarke BL (ref51) 1995; 43
Hanks LJ (ref32) 2015; 10
Abrahamsen B (ref41) 2021; 109
Costello CL (ref84) 2019; 134
Kates SL (ref70) 2016; 47 Suppl 1
Manghat P (ref2) 2014; 51
Regidor B (ref83) 2021; 100
Li X (ref60) 2015; 8
Mhaskar R (ref76) 2017; 12
Yeung SM (ref34) 2020; 20
Wu X (ref56) 2019; 98
Min HK (ref65) 2013; 14
Filipová L (ref37) 2021; 67
Adachi T (ref59) 1982; 36
Luni FK (ref67) 2016; 23
Chakhtoura M (ref75) 2021; 50
Goto S (ref52) 2016; 9
Portales-Castillo I (ref78) 2022; 80
Adhikari S (ref19) 2021; 14
Nakashima A (ref31) 2018; 8
Turner JJ (ref74) 2017; 17
Wen Wu L (ref95) 2020; 6
Reintam Blaser A (ref4) 2021; 40
Crotti C (ref42) 2021; 152
Notarfranchi L (ref16) 2021; 144
Kumar SK (ref86) 2019; 33
Narvaez J (ref44) 2005; 72
Zheng G (ref45) 2021; 46
Panaroni C (ref14) 2017; 15
Masuda H (ref79) 2017; 13
Jakubowiak AJ (ref85) 2012; 120
Foreman JW (ref50) 2019; 66
Griffin PT (ref62) 2015; 121
Buttemer S (ref57) 2011; 2011
Takai E (ref24) 1996; 78
Suvannasankha A (ref47) 2015; 6
Felsenfeld AJ (ref7) 2012; 60
Gnant M (ref73) 2009; 360
Lin M (ref48) 2022; 2022
Bustoros M (ref87) 2019; 134
Terzi Demirsoy E (ref49) 2022; 38
McClung MR (ref68) 2003; 32
Yang M (ref39) 2019; 48
Perazella MA (ref77) 2008; 74
Florenzano P (ref36) 2021; 108
Malhotra A (ref93) 1999; 131
Patel N (ref17) 2005; 30
Das S (ref55) 2019; 11
Pratt CB (ref58) 1991; 9
van der Vaart A (ref33) 2021; 135
Coleman RE (ref71) 2011; 49
Megapanou E (ref15) 2020; 43
Chong WH (ref38) 2011; 18
Mao Z (ref91) 2012; 105
Li Y (ref21) 2020; 42
Sanders PW (ref53) 2012; 23
Yin Z (ref35) 2018; 4
Stewart I (ref46) 2006; 39
Loghman-Adham M (ref92) 1997; 30
Simic P (ref27) 2021; 30
Kaur U (ref81) 2016; 11
Wang R (ref10) 2021; 14
References_xml – volume: 46
  year: 2017
  ident: ref28
  article-title: Fibroblast growth factor 23-mediated bone disease
  publication-title: Endocrinol Metab Clin North Am
  doi: 10.1016/j.ecl.2016.09.013
– volume: 46
  year: 2021
  ident: ref45
  article-title: A case of hypophosphatemia due to oncogenic osteomalacia in a patient with natural killer T-cell lymphoma
  publication-title: Kidney Blood Press Res
  doi: 10.1159/000516390
– volume: 131
  year: 1999
  ident: ref93
  article-title: Polyclonal hyperglobulinemia and spurious hypophosphatemia
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-131-4-199908170-00026
– volume: 33
  year: 2019
  ident: ref86
  article-title: Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
  publication-title: Leukemia
  doi: 10.1038/s41375-019-0384-1
– volume: 8
  year: 2018
  ident: ref31
  article-title: Association between resistin and fibroblast growth factor 23 in patients with type 2 diabetes mellitus
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-32432-z
– volume: 4
  year: 2018
  ident: ref35
  article-title: Tumor-induced osteomalacia
  publication-title: Osteoporos Sarcopenia
  doi: 10.1016/j.afos.2018.12.001
– volume: 43
  year: 2020
  ident: ref15
  article-title: Drug-induced hypophosphatemia: current insights
  publication-title: Drug Saf
  doi: 10.1007/s40264-019-00888-1
– volume: 78
  year: 1996
  ident: ref24
  article-title: Tumor-induced hypercalcemia and parathyroid hormone-related protein in lung carcinoma
  publication-title: Cancer
  doi: 10.1002/(SICI)1097-0142(19961001)78:7<1384::AID-CNCR3>3.0.CO;2-L
– volume: 10
  year: 2015
  ident: ref32
  article-title: Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0122885
– volume: 20
  year: 2020
  ident: ref34
  article-title: Fibroblast growth factor 23 and adverse clinical outcomes in type 2 diabetes: a bitter-sweet symphony
  publication-title: Curr Diab Rep
  doi: 10.1007/s11892-020-01335-7
– volume: 48
  year: 2019
  ident: ref39
  article-title: Molecular imaging in diagnosis of tumor-induced osteomalacia
  publication-title: Curr Probl Diagn Radiol
  doi: 10.1067/j.cpradiol.2018.06.005
– volume: 23
  year: 2016
  ident: ref67
  article-title: Fanconi syndrome and antiretrovirals: it is never too late
  publication-title: Am J Ther
  doi: 10.1097/MJT.0000000000000095
– volume: 23
  year: 2012
  ident: ref53
  article-title: Mechanisms of light chain injury along the tubular nephron
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2012040388
– volume: 15
  year: 2019
  ident: ref26
  article-title: Renal and extrarenal effects of fibroblast growth factor 23
  publication-title: Nat Rev Nephrol
  doi: 10.1038/s41581-018-0087-2
– volume: 6
  year: 2020
  ident: ref95
  article-title: Pseudohypophosphatemia in a patient with multiple myeloma
  publication-title: AACE Clin Case Rep
  doi: 10.4158/ACCR-2020-0389
– volume: 21
  year: 1998
  ident: ref5
  article-title: Hypophosphatemia-induced neuropathy: clinical and electrophysiologic findings
  publication-title: Muscle Nerve
  doi: 10.1002/(sici)1097-4598(199805)21:5<650::aid-mus14>3.0.co;2-z
– volume: 56
  year: 2019
  ident: ref40
  article-title: Tumor-induced osteomalacia - current imaging modalities and a systematic approach for tumor localization
  publication-title: Clin Imaging
  doi: 10.1016/j.clinimag.2019.04.007
– volume: 225
  year: 2017
  ident: ref23
  article-title: Hypophosphatemia after hepatectomy or pancreatectomy: role of the nicotinamide phosphoribosyltransferase
  publication-title: J Am Coll Surg
  doi: 10.1016/j.jamcollsurg.2017.06.012
– volume: 13
  year: 2017
  ident: ref79
  article-title: Severe hypophosphatemia following denosumab administration in a hemodialysis patient with progressive prostate cancer
  publication-title: Urol Case Rep
  doi: 10.1016/j.eucr.2016.11.019
– volume: 12
  year: 2021
  ident: ref90
  article-title: Cortisol and phosphate homeostasis: Cushing's syndrome is associated with reversible hypophosphatemia
  publication-title: Front Endocrinol (Lausanne)
  doi: 10.3389/fendo.2021.733793
– volume: 98
  year: 2019
  ident: ref56
  article-title: Bortezomib-based chemotherapy can improve renal and tubular functions in patients with light chain-associated Fanconi syndrome
  publication-title: Ann Hematol
  doi: 10.1007/s00277-018-3572-6
– volume: 29
  year: 2016
  ident: ref80
  article-title: A case of severe, prolonged, refractory hypophosphatemia after zoledronic acid administration
  publication-title: J Pharm Pract
  doi: 10.1177/0897190015624050
– volume: 105
  year: 2012
  ident: ref91
  article-title: Spurious hypophosphatemia associated with monoclonal paraproteinemia
  publication-title: QJM
  doi: 10.1093/qjmed/hcr104
– volume: 9
  year: 2016
  ident: ref52
  article-title: Serum FGF23 levels may not be associated with serum phosphate and 1,25-dihydroxyvitamin D levels in patients with Fanconi syndrome-induced hypophosphatemia
  publication-title: Clin Kidney J
  doi: 10.1093/ckj/sfw086
– volume: 51
  year: 2014
  ident: ref29
  article-title: Fibroblast growth factor 23
  publication-title: Ann Clin Biochem
  doi: 10.1177/0004563213510708
– volume: 12
  year: 1997
  ident: ref43
  article-title: Tumor-induced osteomalacia: clinical and basic studies
  publication-title: J Bone Miner Res
  doi: 10.1359/jbmr.1997.12.9.1502
– volume: 9
  year: 1991
  ident: ref58
  article-title: Ifosfamide, Fanconi's syndrome, and rickets
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1991.9.8.1495
– volume: 30
  year: 1997
  ident: ref92
  article-title: Spurious hypophosphatemia in a patient with multiple myeloma
  publication-title: Am J Kidney Dis
  doi: 10.1016/s0272-6386(97)90319-x
– volume: 116
  year: 2021
  ident: ref66
  article-title: Deferasirox-associated Fanconi syndrome in adult patients with transfusional iron overload
  publication-title: Vox Sang
  doi: 10.1111/vox.13064
– volume: 11
  year: 2016
  ident: ref81
  article-title: Zoledronate induced hypocalcemia and hypophosphatemia in osteoporosis: a cause of concern
  publication-title: Curr Drug Saf
  doi: 10.2174/1574886311666160426141647
– volume: 43
  year: 1995
  ident: ref51
  article-title: Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features
  publication-title: Clin Endocrinol (Oxf)
  doi: 10.1111/j.1365-2265.1995.tb02621.x
– volume: 30
  year: 2005
  ident: ref17
  article-title: Hyperparathyroidism accompanying multiple myeloma
  publication-title: Clin Nucl Med
  doi: 10.1097/01.rlu.0000170012.06271.76
– volume: 42
  year: 2020
  ident: ref21
  article-title: Electrolyte and acid-base disorders in cancer patients and its impact on clinical outcomes: evidence from a real-world study in China
  publication-title: Ren Fail
  doi: 10.1080/0886022X.2020.1735417
– volume: 22
  year: 2021
  ident: ref13
  article-title: Myeloma bone disease: a comprehensive review
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms22126208
– volume: 134
  year: 2019
  ident: ref84
  article-title: Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma: results of a safety run-in analysis
  publication-title: Blood
  doi: 10.1182/blood-2019-123506
– volume: 7
  year: 2007
  ident: ref11
  article-title: Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2189
– volume: 42
  year: 2008
  ident: ref12
  article-title: The pathogenesis of the bone disease of multiple myeloma
  publication-title: Bone
  doi: 10.1016/j.bone.2008.01.027
– volume: 87
  year: 2021
  ident: ref22
  article-title: Implications of postpancreatectomy hypophosphatemia
  publication-title: Am Surg
  doi: 10.1177/0003134820949517
– volume: 12
  year: 2017
  ident: ref76
  article-title: Bisphosphonates in multiple myeloma: an updated network meta-analysis
  publication-title: Cochrane Database Syst Rev
  doi: 10.1002/14651858.CD003188.pub4
– volume: 6
  year: 2015
  ident: ref47
  article-title: FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.3794
– volume: 107
  year: 2014
  ident: ref61
  article-title: Drug-induced renal Fanconi syndrome
  publication-title: QJM
  doi: 10.1093/qjmed/hct258
– volume: 38
  year: 2022
  ident: ref49
  article-title: Prognostic value of serum soluble klotho and fibroblast growth factor-23 in multiple myeloma patients
  publication-title: Indian J Hematol Blood Transfus
  doi: 10.1007/s12288-021-01470-5
– volume: 22
  year: 2017
  ident: ref20
  article-title: Incidence of hypophosphatemia in advanced cancer patients: a recent report from a single institution
  publication-title: Int J Clin Oncol
  doi: 10.1007/s10147-016-1063-0
– volume: 332
  year: 1990
  ident: ref25
  article-title: Action of tumoral PTH-related peptide on phosphate and calcium transport
  publication-title: Prog Clin Biol Res
– volume: 67
  year: 2021
  ident: ref37
  article-title: Tumor induced osteomalacia
  publication-title: Vnitr Lek
  doi: 10.36290/vnl.2021.130
– volume: 2011
  year: 2011
  ident: ref57
  article-title: Ifosfamide induced Fanconi syndrome
  publication-title: BMJ Case Rep
  doi: 10.1136/bcr.10.2011.4950
– volume: 60
  year: 2012
  ident: ref7
  article-title: Approach to treatment of hypophosphatemia
  publication-title: Am J Kidney Dis
  doi: 10.1053/j.ajkd.2012.03.024
– volume: 12
  year: 1982
  ident: ref18
  article-title: Coexistent multiple myeloma and primary hyperparathyroidism
  publication-title: JAMA
– volume: 50
  year: 2021
  ident: ref75
  article-title: Treatment of hypercalcemia of malignancy
  publication-title: Endocrinol Metab Clin North Am
  doi: 10.1016/j.ecl.2021.08.002
– volume: 74
  year: 2008
  ident: ref77
  article-title: Bisphosphonate nephrotoxicity
  publication-title: Kidney Int
  doi: 10.1038/ki.2008.356
– volume: 14
  year: 2013
  ident: ref65
  article-title: Rifampin-associated tubulointersititial nephritis and Fanconi syndrome presenting as hypokalemic paralysis
  publication-title: BMC Nephrol
  doi: 10.1186/1471-2369-14-13
– volume: 100
  year: 2021
  ident: ref83
  article-title: Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study
  publication-title: Ann Hematol
  doi: 10.1007/s00277-020-04351-5
– volume: 120
  year: 2012
  ident: ref85
  article-title: A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
  publication-title: Blood
  doi: 10.1182/blood-2012-04-422683
– volume: 36
  year: 1982
  ident: ref59
  article-title: Prognostic factors in multiple myeloma treated with prednisolone and sequential melphalan and ifosfamide: MIP combination chemotherapy
  publication-title: Acta Med Okayama
  doi: 10.18926/AMO/30707
– volume: 27
  year: 2016
  ident: ref54
  article-title: Impaired lysosomal function underlies monoclonal light chain-associated renal Fanconi syndrome
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2015050581
– volume: 8
  year: 2015
  ident: ref60
  article-title: The clinical activity of arsenic trioxide, ascorbic acid, ifosfamide and prednisone combination therapy in patients with relapsed and refractory multiple myeloma
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S81022
– volume: 134
  year: 2019
  ident: ref87
  article-title: Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma
  publication-title: Blood
  doi: 10.1182/blood-2019-128519
– volume: 23
  year: 1994
  ident: ref63
  article-title: Aminoglycoside-induced Fanconi's syndrome
  publication-title: Am J Kidney Dis
  doi: 10.1016/s0272-6386(12)80820-1
– volume: 14
  year: 2021
  ident: ref19
  article-title: Hypophosphatemia in cancer patients
  publication-title: Clin Kidney J
  doi: 10.1093/ckj/sfab078
– volume: 360
  year: 2009
  ident: ref73
  article-title: Endocrine therapy plus zoledronic acid in premenopausal breast cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0806285
– volume: 72
  year: 2005
  ident: ref44
  article-title: Acquired hypophosphatemic osteomalacia associated with multiple myeloma
  publication-title: Joint Bone Spine
  doi: 10.1016/j.jbspin.2004.10.012
– volume: 66
  year: 2019
  ident: ref50
  article-title: Fanconi syndrome
  publication-title: Pediatr Clin North Am
  doi: 10.1016/j.pcl.2018.09.002
– volume: 2022
  year: 2022
  ident: ref48
  article-title: Treating 'osteoporosis': a near miss in an unusual case of FGF-23-mediated hypophosphataemic osteomalacia
  publication-title: Endocrinol Diabetes Metab Case Rep
  doi: 10.1530/EDM-22-0300
– volume: 32
  year: 2003
  ident: ref68
  article-title: Bisphosphonates
  publication-title: Endocrinol Metab Clin North Am
  doi: 10.1016/s0889-8529(02)00079-8
– volume: 363
  year: 2010
  ident: ref69
  article-title: Bisphosphonates for osteoporosis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMct1004903
– volume: 36
  year: 2021
  ident: ref8
  article-title: Hypophosphatemia and outcomes in ICU: a systematic review and meta-analysis
  publication-title: J Intensive Care Med
  doi: 10.1177/0885066620940274
– volume: 103
  year: 2010
  ident: ref89
  article-title: Medication-induced hypophosphatemia: a review
  publication-title: QJM
  doi: 10.1093/qjmed/hcq039
– volume: 8
  year: 2020
  ident: ref1
  article-title: Approach to patients with hypophosphataemia
  publication-title: Lancet
  doi: 10.1016/S2213-8587(19)30426-7
– volume: 51
  year: 2018
  ident: ref64
  article-title: Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis
  publication-title: Eur Respir J
  doi: 10.1183/13993003.02187-2017
– volume: 51
  year: 2014
  ident: ref2
  article-title: Phosphate homeostasis and disorders
  publication-title: Ann Clin Biochem
  doi: 10.1177/0004563214521399
– volume: 14
  year: 2021
  ident: ref30
  article-title: FGF-23 (fibroblast growth factor-23) and cardiorenal interactions
  publication-title: Circ Heart Fail
  doi: 10.1161/CIRCHEARTFAILURE.121.008385
– volume: 47 Suppl 1
  year: 2016
  ident: ref70
  article-title: How do bisphosphonates affect fracture healing?
  publication-title: Injury
  doi: 10.1016/S0020-1383(16)30015-8
– volume: 325
  year: 2003
  ident: ref94
  article-title: Monoclonal gammopathy and spurious hypophosphatemia
  publication-title: Am J Med Sci
  doi: 10.1097/00000441-200302000-00007
– volume: 50
  year: 2021
  ident: ref9
  article-title: Hypophosphatemia is more common and is prognostic of poorer outcomes in severe alcoholic pancreatitis
  publication-title: Pancreas
  doi: 10.1097/MPA.0000000000001952
– volume: 135
  year: 2021
  ident: ref33
  article-title: Phosphate and fibroblast growth factor 23 in diabetes
  publication-title: Clin Sci (Lond)
  doi: 10.1042/CS20201290
– volume: 352
  year: 2016
  ident: ref6
  article-title: Hypophosphatemia-induced cardiomyopathy
  publication-title: Am J Med Sci
  doi: 10.1016/j.amjms.2016.04.013
– volume: 8
  year: 2006
  ident: ref72
  article-title: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr1384
– volume: 108
  year: 2021
  ident: ref36
  article-title: Tumor-induced osteomalacia
  publication-title: Calcif Tissue Int
  doi: 10.1007/s00223-020-00691-6
– volume: 152
  year: 2021
  ident: ref42
  article-title: Tumor induced osteomalacia: a single center experience on 17 patients
  publication-title: Bone
  doi: 10.1016/j.bone.2021.116077
– volume: 11
  year: 2019
  ident: ref55
  article-title: Partial Fanconi syndrome induced by ifosfamide
  publication-title: Cureus
  doi: 10.7759/cureus.3947
– volume: 80
  year: 2022
  ident: ref78
  article-title: Zoledronic acid-associated Fanconi syndrome in patients with cancer
  publication-title: Am J Kidney Dis
  doi: 10.1053/j.ajkd.2021.12.015
– volume: 40
  year: 2021
  ident: ref4
  article-title: Hypophosphatemia in critically ill adults and children - a systematic review
  publication-title: Clin Nutr
  doi: 10.1016/j.clnu.2020.09.045
– volume: 39
  year: 2006
  ident: ref46
  article-title: Elevated serum FGF23 concentrations in plasma cell dyscrasias
  publication-title: Bone
  doi: 10.1016/j.bone.2006.01.163
– volume: 109
  year: 2021
  ident: ref41
  article-title: Epidemiology of tumor-induced osteomalacia in Denmark
  publication-title: Calcif Tissue Int
  doi: 10.1007/s00223-021-00843-2
– volume: 144
  year: 2021
  ident: ref16
  article-title: Concomitant primary hyperparathyroidism in patients with multiple myeloma: a possible link?
  publication-title: Acta Haematol
  doi: 10.1159/000509768
– volume: 17
  year: 2017
  ident: ref74
  article-title: Hypercalcaemia - presentation and management
  publication-title: Clin Med (Lond)
  doi: 10.7861/clinmedicine.17-3-270
– volume: 61
  year: 2010
  ident: ref3
  article-title: Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23
  publication-title: Annu Rev Med
  doi: 10.1146/annurev.med.051308.111339
– volume: 15
  year: 2017
  ident: ref14
  article-title: Myeloma and bone disease
  publication-title: Curr Osteoporos Rep
  doi: 10.1007/s11914-017-0397-5
– volume: 49
  year: 2011
  ident: ref71
  article-title: Bisphosphonates in oncology
  publication-title: Bone
  doi: 10.1016/j.bone.2011.02.003
– volume: 121
  year: 2015
  ident: ref62
  article-title: A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma
  publication-title: Cancer
  doi: 10.1002/cncr.29533
– volume: 18
  year: 2011
  ident: ref38
  article-title: Tumor-induced osteomalacia
  publication-title: Endocr Relat Cancer
  doi: 10.1530/ERC-11-0006
– volume: 63
  year: 2022
  ident: ref82
  article-title: A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma
  publication-title: Leuk Lymphoma
  doi: 10.1080/10428194.2021.2005044
– volume: 14
  year: 2021
  ident: ref10
  article-title: Hypophosphatemia at admission is associated with increased mortality in COVID-19 patients
  publication-title: Int J Gen Med
  doi: 10.2147/IJGM.S319717
– volume: 30
  year: 2021
  ident: ref27
  article-title: Glycerol-3-phosphate and fibroblast growth factor 23 regulation
  publication-title: Curr Opin Nephrol Hypertens
  doi: 10.1097/MNH.0000000000000715
– volume: 106
  year: 2005
  ident: ref88
  article-title: A phase I-II trial of bortezomib (Velcade) (VC) and oral cyclophosphamide (Cy) plus prednisone (P) for relapsed/refractory multiple myeloma (MM)
  publication-title: Blood
  doi: 10.1182/blood.V106.11.2556.2556
SSID ssj0001072070
Score 2.2231297
SecondaryResourceType review_article
Snippet Hypophosphatemia is among the most common electrolyte abnormalities, especially among patients with underlying malignancies, and is frequently associated with...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage e40487
SubjectTerms Bisphosphonates
Cancer
Diabetes
Disease
Endocrine system
Fibroblasts
Growth factors
Hypercalcemia
Internal Medicine
Kidneys
Metabolism
Multiple myeloma
Nephrology
Oncology
Phosphates
Phosphorus
Regulation
Squamous cell carcinoma
Tomography
Tumors
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1NS-RAEC1WBfGy-G38IoIeo0l3ujs5ybKsDMIsHhTnFvpLZkCTaGYO_vutSjLjjoLnbpLwuqh66X79CuA8NlpbrIyRyIyM0iefRLlvlVMiMZpRf2u6Ozz8KwcP6e1IjPoNt6aXVc5zYpuoXWVpj_wKy2CisHoJeV2_RtQ1ik5X-xYaK7BG1mUk6VIj9bHHEiuGId3p3ZUS-ZWdvflZc5li3KrlSvSFXn5WSf5Xdm424WfPF8Nf3QJvwQ9fbsP6sD8R3wE2eK-relw19RhZ48tEh5MyvOvMUpvwcTIdh8NeMxgO3_1z9aJ34eHmz_3vQdT3QYgsj-NpxJyxifKOzOSz3GXUxSDj0nHHtGWKSc2ZjX0W6yw1Eikzsi6LRI0nnrtUCL4Hq2VV-gMIhcnlk0oNc0gjUsm1dJmzBh9kcnLSCeBijklRd3YXBf4mEHZFh13RYhfA8Rywog_6pvhYogDOFsMYrnQGoUtfzWgOziLXsjSA_Q7fxYu4IjvCmAWQLSG_mEBW2Msj5WTcWmIjTcLEEueH33_XEWxQu3iSeiXiGFanbzN_gqRiak7byPkHDtnNWA
  priority: 102
  providerName: ProQuest
Title Hypophosphatemia in Patients With Multiple Myeloma
URI https://www.ncbi.nlm.nih.gov/pubmed/37342302
https://www.proquest.com/docview/2831719056
https://www.proquest.com/docview/2828361214
https://pubmed.ncbi.nlm.nih.gov/PMC10279409
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fS8MwED50gvgi_rY6RwV97GyTtmmfREUZQmWIw72VpImsoO3cVnD_vZf-GM755HMuLXx36X1pLt8BXNiC8wQzo-UFwrfcN-VYoSorpzxHcKL7W-u7w9GT3xu4j0NvuAZNt9EawOmfWzvdT2owee9-fc6vccEjf-0y5oVXSTFRxbTrYjCyddjAnMT0Eo1qol_-bbEZweCuKt9XJi3npBWi-bte8kcCetiB7Zo5mjeVq3dhTWV7sBnVZ-P7QHrzcT4e5dPxCPnjR8rNNDP7lWzq1HxNZyMzqqsHzWiu3vMPfgCDh_uXu55Vd0SwEmrbM4tIkThMSS0rH4Qy0P0MAupLKglPCCM-pySxVWDzwBU-kmfkXwlSNuooKl3Po4fQyvJMHYPpidB_Y64gEgmF61Puy0AmAh8kQq2pY8Blg0k8roQvYtwwaOziCru4xM6AdgNY3HgvRs6CPgiRXBlwvhjGwNWnETxTeaFt0Errl7kGHFX4Ll5EmRYmtIkBwRLyCwMtir08kqWjUhwbCRN-Yuzw5P9TT2FLN5XXBWGO14bWbFKoM6QeM9GBdTZkHdi4vX_qP3fKGPsGs2_e3A
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bT9RAFD4hS6K-GO8UUWsij5V2ZjptHwwBhCxCN8RA5K3Ojewm0ha6G7N_yt_oOdt2cTXxjeeZtM3Xc_lm5sx3AD6EWimDmTGIUy0DceWiIHOLyqk40opRf2u6O5yP5PBCfLmML9fgV38Xhsoq-5i4CNS2MrRHvoNpMEowe8Vyt74JqGsUna72LTRaszhx85-4ZGs-HX_G_7vN2NHh-cEw6LoKBIaH4TRgVpsocZak2dPMptQTIOXScsuUYQmTijMTujRUqdASCShyGIO0h0eOWxFTlwgM-euC41JmAOv7h6Ozr3e7OmHC0InaCvskibMdM7t1s-ajQE9JVnPfP4T277rMPxLd0RN43DFUf681qaew5spn8CDvzuCfAxvO66oeV009Rp56PVH-pPTPWnnWxv82mY79vKtS9PO5-1FdqxdwcS8YvYRBWZVuA_xYZ_IqEZpZJC5CciVtao3GB-mMtHs82O4xKepWYKPAhQlhV7TYFQvsPNjqASs6N2uKO6Pw4P1yGB2ETj1U6aoZzcFZpJMmPHjV4rt8EU9IADFkHqQryC8nkPj26kg5GS9EuJGYYSgLs83_f9c7eDg8z0-L0-PRyWt4RM3qqdAsirdgML2duTdIaab6bWdHPny_b9P9DeYZCcQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB5VRaq4IN4YChiJHk3sXe-ufUAIUaKUkqoHKnIz-4oSidqmToTy1_h1zPiREpC49bwr2_o8j293Z78BeB0brS1mxkhkRkbp3CdR7tvKKZEYzai_Nd0dnp7JyUX6aSZme_BruAtDZZVDTGwDtass7ZGPMA0mCrOXkKN5XxZxfjx-V_-IqIMUnbQO7TQ6Ezn1m5-4fGvenhzjvz5ibPzxy4dJ1HcYiCyP41XEnLGJ8o5k2rPcZdQfIOPScce0ZYpJzZmNfRbrLDUSySjyGYsUiCeeu1RQxwgM_7cUFwn5mJqp6_2dWDF0p67WXimRj-z6yq-bNyn6jNrNgv9Q278rNP9IeeO7cKfnquH7zrjuwZ4v78PBtD-NfwBssqmrelE19QIZ6-VSh8syPO-EWpvw63K1CKd9vWI43fjv1aV-CBc3gtAj2C-r0j-BUJhczlVqmEMKk0qupcucNfggk5OKTwBHAyZF3UltFLhEIeyKDruixS6AwwGwone4prg2jwBebYfRVej8Q5e-WtMcnEWKaWkAjzt8ty_iiqQQYxZAtoP8dgLJcO-OlMtFK8eNFA2DWpw__f93vYQDNNji88nZ6TO4TV3rqeIsEYewv7pa--fIbVbmRWtEIXy7aav9DWYVDJQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hypophosphatemia+in+Patients+With+Multiple+Myeloma&rft.jtitle=Cur%C4%93us+%28Palo+Alto%2C+CA%29&rft.au=Cancarevic%2C+Ivan&rft.au=Ilyas%2C+Usman&rft.au=Nassar%2C+Mahmoud&rft.date=2023-06-15&rft.pub=Cureus&rft.eissn=2168-8184&rft.volume=15&rft.issue=6&rft_id=info:doi/10.7759%2Fcureus.40487&rft.externalDocID=PMC10279409
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2168-8184&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2168-8184&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2168-8184&client=summon